|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **n Number of patients\*** | **Dose ≤ 10.5 Gy** | **Dose > 10.5 Gy** | **p** |
| **Relapse**  |  |  |  |  |
| NoYes | 166 (69.7%)72 (30.3%) | 67 (40.4%)29 (40.3%) | 99 (59.6%)43 (59.7%) | 0.990 |
| **Secondary Malignancy** |  |  |  |  |
| NoYes | 206 (86.6%)32 (13.4%) | 79 (38.3%)17 (53.1%) | 127 (61.7%) 15 (46.9%) | 0.184 |
| **Cardiac Disease** |  |  |  |  |
| NoYes | 215 (90.3%)23 (9.7%) | 84 (39.1%)12 (52.2%) | 131 (60.9%)11 (47.8%) | 0.225 |
| **Pulmonary Disease** |  |  |  |  |
| NoYes | 208 (87.4%)30 (12.6%) | 76 (36.5%)20 (66.7%) | 132 (63.5%)10 (33.3%) | **0.002** |
| **Hepatic Disease** |  |  |  |  |
| NoYes | 237 (99.6%)1 (0.4%) | 95 (40.1%))1 (100%) | 142 (59.9%)0 | 0.225 |
| **Renal Damage** |  |  |  |  |
| No Yes | 163 (68.5%)75 (31.5%) | 55 (33.7%)41 (54.7%) | 108 (66.3%)34 (45.3%) | **0.002** |
| **Endocrine Disorders** |  |  |  |  |
| NoYes | 206 (86.6%)32 (13.4%) | 81 (39.3%)15 (46.9%) | 125 (60.7%)17 (53.1%) | 0.420 |
| **Cataract** |  |  |  |  |
| NoYes | 216 (90.8)22 (9.2%) | 86 (39.8%)10 (45.5%) | 130 (60.2%)12 (54.5%) | 0.609 |
| **Acute Toxicity** |  |  |  |  |
| NoYes | 162 (68.1%)76 (31.9%) | 64 (39.5%)32 (42.1%) | 98 (60.5%)44 (57.9%) | 0.705 |